Help Improve Outcomes

Prolonged inflammation can impact Urology patients’ outcomes.  

Clarix® is the answer.

Clarix 1K is a cryopreserved ultra-thick human birth tissue allograft used as an adjunct for surgical applications. Clarix 1K helps support a regenerative healing environment and the restoration of urinary and sexual function after Robot-Assisted Radical Prostatectomy (RARP). 1-2

Optimal Patient Outcomes Matter.

At the time of surgery, give that one chance its best chance with Clarix.

Images courtesy of Mutahar Ahmed, MD, Hackensack Meridian Health, Hackensack, NJ

The Proof is in the Evidence

Improved clinical outcomes are supported by our published clinical evidence in  Urologic Oncology applications:

83% of patients achieved continence at 3-months when Clarix was used as an adjunct in RARP.1

75% of patients achieved potency at 6-months post-RARP with the use of Clarix.2

Clarix is an ultra-thick allograft providing ease of use in robotic procedures.

Allograft placement over Neurovascular Bundles (NVBs) after prostate resection.

Introducing allograft into the surgical site using a single-port robot.

Putting the Numbers to Life: Clinical Case Studies

Please click the image to download the full case study.

Robotic-Assisted Radical Prostatectomy (RARP)

  • Patient: 52-year-old male, Gleason 7 (4+3) prostate cancer, PSA 4.5, no metastasis.
  • Treatment: RARP with nerve sparing due to life expectancy and disease status. Clarix 1K used over NVBs.
  • Outcome: Recovery of urinary and sexual function after RARP.

Ureteral Reconstruction

  • Patient: 78-year-old male with worsening renal function and mild left flank pain, history of prostate cancer treated with brachytherapy and external beam radiation 9-years prior.
  • Treatment: CT scan revealed left hydronephrosis and a stricture below the iliac artery; single-port robotic left ureterectomy with psoas hitch and reimplantation; anastomosis wrapped with ultra-thick AM (Clarix® 1K).
  • Outcome: Discharged within 24-hours, Foley catheter removed at 7-days, ureteral stent removed at 4-weeks; no complications, improved renal function, and no hydronephrosis over 12-month follow-up.

Vesicovaginal Fistula

  • Patient: 49-year-old female with a history of four cesarean surgeries and total abdominal hysterectomy for large fibroid uterus and menorrhagia.
  • Treatment: Cystogram revealed a large bladder-vaginal fistula; cystoscopy identified two large fistulas and thinning of bladder mucosa; surgical reconstruction performed.
  • Outcome: Discharged after one day, Foley catheter removed at 7-days post-op, maintained continence at 5-month follow-up, and patient was satisfied with the outcome.

Fill out the form below to download clinical case studies:  

  • By clicking the button below, I agree to receive marketing communications from BioTissue Holdings Inc. I am aware that I can unsubscribe at any time.
  • This field is for validation purposes and should be left unchanged.
References
Ahmed M, et al. J Robot Surg. 2020 Apr;14(2):283-289. doi: 10.1007/s11701-019-00972-9.
Stites, J., et al., Initial Experience with a Bioregenerative Matrix on Erectile Function Following Nerve-Sparing Robot-Assisted Laparoscopic Radical Prostatectomy, in World Congress of Endourology. 2018: Paris, France.
Images courtesy of: Mutahar Ahmed, MD, Hackensack Meridian Health, Hackensack, NJ.